Kimberly Cline
Psychiatric/Mental Health · Poplar Bluff, MONPI 1932665742
Payments from drug & device makers
Across 284 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- Johnson & Johnson$817
- Neurocrine Biosciences, Inc.$507
- Otsuka America Pharmaceutical, Inc.$457
- AbbVie$372
- Axsome Therapeutics, Inc.$317
- plus $2K from 13 others
What the payments were for
- Food & beverage$5,468100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 70 | $1,518 |
| Johnson & Johnson | 51 | $817 |
| Neurocrine Biosciences, Inc. | 30 | $507 |
| Otsuka America Pharmaceutical, Inc. | 20 | $457 |
| AbbVie | 19 | $372 |
| Axsome Therapeutics, Inc. | 10 | $317 |
| Lundbeck LLC | 15 | $306 |
| Teva Pharmaceuticals USA, Inc. | 13 | $255 |
| Indivior Inc. | 13 | $215 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $196 |
| Vanda Pharmaceuticals Inc. | 8 | $148 |
| E.r. Squibb & Sons, L.L.C. | 5 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $95 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
| Merck | 3 | $42 |
| Sunovion Pharmaceuticals Inc. | 3 | $33 |
| Novo Nordisk | 1 | $24 |
| Almatica Pharma LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$950
- ARISTADA$894
- ARISTADA INITIO$223
- ABILIFY MAINTENA$120
- ABILIFY ASIMTUFII$120
- Auvelity$120
How this compares
$5,488 in reported general payments places this provider in the 85th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 40 | $111,507 |
| AustedoDeutetrabenazine | 11 | $53,249 |
| VraylarCariprazine Hcl | 35 | $52,908 |
| Invega SustennaPaliperidone Palmitate | 18 | $52,456 |
| RexultiBrexpiprazole | 33 | $49,309 |
| AristadaAripiprazole Lauroxil | 13 | $40,264 |
| LybalviOlanzapine/Samidorphan Malate | 22 | $37,912 |
| TrintellixVortioxetine Hydrobromide | 21 | $12,734 |
| Aripiprazole | 145 | $3,686 |
| Atomoxetine Hcl | 19 | $3,584 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $2,883 |
| Lurasidone Hcl | 46 | $2,377 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 41 | $2,174 |
| Vilazodone Hcl | 22 | $2,171 |
| Buspirone Hcl | 142 | $2,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $457 | $160,81673 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,518 | $78,17635 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $255 | $53,24911 claims |
| AbbVieVraylar | $372 | $52,90835 claims |
| Johnson & JohnsonInvega Sustenna | $817 | $52,45618 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $95 | $12,73421 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $482100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Poplar Bluff
- Kristerpher BrimberryPoplar Bluff$74K
- Camellia VermillionPoplar Bluff$6K
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Matthew LindquistSt Louis$42K
- Stacy EmersonKennett$25K
- Jeffery DavisCreve Coeur$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.